Poland’s largest pharmaceutical company, Polpharma, will receive PLN 30 million to develop production technology for RNA-based drugs, Poland’s Minister of Development Funds and Regional Policy has announced.
Posting on X, Katarzyna Pełczyńska-Nałęcz added that if the project was successful, Poland could develop its own original drug.
She said: “We have signed the first agreement with the Polish Critical Technologies Support Fund! It concerns a key area: drug sovereignty. PLN 30 million goes to Polpharma for the development of RNA drug production technology.
“These drugs ‘teach’ the body how to produce the proteins that help fight diseases.”
She added that the drugs “are an absolute revolution in the treatment of heart and circulatory system diseases.
“If everything goes according to plan, we will have our own, unique drug – here in Poland.”
The Critical Technologies Support Fund was established in June 2025. Its total budget amounts to PLN 4 billion and it was created through changes to the European Funds for the Modern Economy (FENG) programme.
The fund is intended for companies implementing research and development projects and investments in sectors considered crucial to the future of the Polish economy.
When announcing the establishment of the fund in May, Pełczyńska-Nałęcz said that eligible sectors include biotechnologies, including medicines and active pharmaceutical ingredients, digital technologies, including cybersecurity, and clean and resource-efficient technologies.
The European Funds for the Modern Economy (FENG) 2021–2027 programme is a continuation of the Innovative Economy 2007–2013 and Smart Growth 2014–2020 programmes. Its objectives include increasing research and innovation potential and expanding the use of advanced technologies. (PAP)
jls/ drag/
tr. RL
